ETCTN A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) inhibitor AT7519M in patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Administratively Completed Completed